Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

NCT02038816 | Terminated Phase 2

• 1 other identifier: CICL670ACA02T
• Study Type: interventional
• Target: 1
• Locations: 1 country
• Sites: 1

Brief Summary

Myelodysplastic syndromes are common blood disorders that can affect as many as one in 1000 Canadians over the age of 65. They are characterized by low blood counts that require frequent blood transfusions. The development of iron overload in these patients is inevitable. The iron deposits in vital organs such as the heart and the liver and can lead to organ dysfunction. Deferasirox is a well-studied drug that helps remove iron from the body. Most people with this disorder die due to progression of their disease to acute leukemia through multiple mechanisms. Iron overload in patients with myelodysplastic syndromes has been shown to be associated with shorter survival, and potentially a higher chance of leukemia. In a certain sub-group of higher risk patients, the drug azacitidine has been shown to decrease the chance of progression to leukemia and death from it. Thus, it is presently the standard of care for these patients. However, 50% of higher risk patients are still unresponsive to this medication, leaving a large group of patients for which other treatment options are emergently needed. Given that a large proportion of higher risk MDS patients fail to respond to azacitidine, and the evidence that iron deposition may lead to increased leukemic transformation, we would like to study whether iron removal from the body with deferasirox potentiates azacitidine in its effects on overall survival, as well as the chance of leukemia transformation. This question needs to be addressed in a randomized controlled trial, and the first step is a preliminary study to determine if the combination of azacitidine and deferasirox has any biologic effect. This study will determine whether this combination leads to blood count improvement over azacitidine alone. If this drug combination ultimately proves more useful than azacitidine alone with respect to survival, this has the potential to impact the care of a large proportion of patients with myelodysplastic syndromes.

Conditions

Myelodysplastic Syndromes

Outcome Measures

Primary Outcomes (1)

• Difference in proportion of patients with hematologic improvement as defined by the IWG criteria30 with the addition of deferasirox to azacitidine compared with azacitidine alone in higher risk non-responding MDS patients after 6 cycles of azacitidine.

  improvement in blood counts or remission status

  6 months

Secondary Outcomes (5)

• Tolerability (defined by the percentage of patients able to remain on deferasirox for 6 cycles concurrent with azacitidine) and safety (type, using CTCAE version 4.0, frequency, severity, and relationship of adverse events to study therapy)

  6 months

• Percentage and absolute change in serum ferritin and labile plasma iron (LPI) between baseline and end of study

  6 months

• Percentage change in CD34 cell intracellular reactive oxygen species (ROS) from baseline to end of study.

  6 months

• Percentage change in erythroid colony forming units (BFU-E and CFU-E) from baseline to end of study

  6 months

• Percentage change in markers of DNA damage (lipid peroxidation, GSH content, and gH2AX expression), and activity of NFkappaB and Akt signaling pathways between baseline and end of study.

  6 months

Study Arms (2)

Deferasirox + Azacitidine

EXPERIMENTAL

Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs

Drug: Deferasirox + Azacitidine; Drug: Azacitidine

Azacitidine

ACTIVE COMPARATOR

Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles

Drug: Azacitidine

Interventions

Deferasirox + Azacitidine DRUG

Deferasirox: 20 mg/kg/d for \< 14ml/kg/mo pRBCs (\~ \<4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients

Also known as: Exjade, Vidaza

Deferasirox + Azacitidine

Azacitidine DRUG

Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles

Also known as: Vidaza

Azacitidine; Deferasirox + Azacitidine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults \>18 yrs of age
• WHO defined MDS with Higher risk MDS (IPSS int-2/high)
• Azacitidine X at least 6 cycles with no hematologic improvement/no disease progression as per IWG 2006 criteria
• Ferritin \>500 µg/L
• If transfusion independent, must have Hb \<110 g/L OR Neutrophils \< 1,000/mL OR Platelets \< 100,000/mL
• ECOG ≤2
• CrCl \>40 ml/min

You may not qualify if:

• Increased ALT (\>300 U/L)
• Uncontrolled infection
• HIV+
• Pregnant or breast-feeding
• Previous and concurrent iron chelation
• Concurrent use of hematopoietic growth factors including erythropoietin, darbepoietin and granulocyte colony stimulating factor
• Concurrent use of other disease modifying agents including cytotoxic chemotherapy, histone deacetylase inhibitors, other hypomethylating agents or lenalidomide

Sponsors & Collaborators

• Sunnybrook Health Sciences Centre: lead
• Novartis: collaborator

Study Sites (1)

Odette Cancer Centre, Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

Location

MeSH Terms

Conditions

Myelodysplastic Syndromes

Interventions

Deferasirox; Azacitidine

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Benzoates; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Triazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Aza Compounds; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleosides

Study Officials

• Rena Buckstein, MD

  Odette Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2014
• First Posted: January 17, 2014
• Study Start: March 1, 2014
• Primary Completion: September 29, 2016
• Study Completion: September 29, 2016
• Last Updated: April 26, 2018

Record last verified: 2018-04

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)